| Literature DB >> 23281734 |
Tzung-Chi Huang1, Chien-Yi Hsiao, Chun-Ru Chien, Ji-An Liang, Tzu-Ching Shih, Geoffrey G Zhang.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2013 PMID: 23281734 PMCID: PMC3552773 DOI: 10.1186/1748-717X-8-3
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Characteristics of study subjects and lesions
| 1 | 71 | NSCLC,NOS # | III | RUL | 62.1 cm3 |
| 2 | 64 | NSCLC, Squamous Cell Cancer | III | LUL | 119.5 cm3 |
| 3 | 49 | Thymoma # | III | | 216.7 cm3 |
| 4 | 62 | Small cell lung cancer | III | RUL | 253.5 cm3 |
| 5 | 54 | Thymoma # | III | | 260.7 cm3 |
| 6 | 52 | Esophagus, Squamous Cell Cancer # | III | | 393.2 cm3 |
| 7 | 41 | NSCLC, Squamous Cell Cancer | III | RLL | 639.8 cm3 |
| 8 | 56 | Esophagus, Squamous Cell Cancer | III | | 660.6 cm3 |
| 9 | 70 | NSCLC, Squamous Cell Cancer | III | Carina bronchial | 716.6 cm3 |
| 10 | 52 | NSCLC, Esophagus, Squamous Cell Cancer # | III | LLL | 732.8 cm3 |
| 11 | 72 | NSCLC, Squamous Cell Cancer | III | LLL | 804.9 cm3 |
The location is labeled as RUL = right upper lobe, RLL = right lower lobe, LUL = left upper lobe and LLL = left lower lobe. NSCLC = non-small cell lung cancer; NOS = not otherwise specified #: resection operation was performed before radiotherapy.
Dose volume constraints for anatomic planning and functional planning used for intensity-modulated radiotherapy (IMRT)
| | | ||||||
|---|---|---|---|---|---|---|---|
| GTV | Maximum dose | 105% | 0% | 50 | 105% | 0% | 50 |
| Minimum dose | 103% | 100% | 450 | 103% | 100% | 450 | |
| CTV | Maximum dose | 105% | 0% | 400 | 105% | 0% | 400 |
| Minimum dose | 102% | 100% | 400 | 102% | 100% | 400 | |
| PTV | Maximum dose | 105% | 0% | 650 | 105% | 0% | 650 |
| Minimum dose | 101% | 100% | 350 | 101% | 100% | 350 | |
| Total lung | Maximum dose | 5 Gy | 30% | 200 | 5 Gy | 30% | 200 |
| Maximum dose | 10 Gy | 25% | 200 | 10 Gy | 25% | 200 | |
| Maximum dose | 20 Gy | 20% | 200 | 20 Gy | 20% | 200 | |
| Functional lung | Maximum dose | | | | 5 Gy | 30% | 250 |
| Maximum dose | | | | 10 Gy | 25% | 250 | |
| Maximum dose | | | | 20 Gy | 20% | 250 | |
| Spinal cord | Maximum dose | 40 Gy | 0% | 300 | 40 Gy | 0% | 300 |
| Spinal cord + 5 mm | Maximum dose | 45 Gy | 0% | 300 | 45 Gy | 0% | 300 |
Figure 1The transverse (a), coronal (b) and sagittal (c) views of a 4D-CT. The arrow indicated the location of the tumor. Corresponding views of 50%-0% (expiration-inspiration) ventilation of this example are shown as in (d), (e) and (f). Low ventilation is noticeable in the tumor region (indicated by the arrow on the CT image) on the ventilation image. The arrows on the CT image set indicate that the right diaphragm motion range was large. This volume change difference can be observed on the ventilation image. The ventilation image is scaled as ΔV/V = 0 as black and 0.5 as white.
Figure 2(a) Dose distribution of an anatomic IMRT treatment plan with high ventilation regions, as an example (b) The dose–(functional) volume histogram (DVH or DFVH) of the highly-functional lung region, at 20%, 30% and 40% for a large volume of NSCLS cancer patient.
Values of V5, V20 and mean lung dose (MLD) in total lung and top 20%, 30% and 40% functional lung regions for all the investigated anatomic treatment plans
| | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 11.6 | 7.1 | 3.8 | 5.1 | 2.6 | 1.6 | 7.9 | 4.4 | 2.6 | 9.4 | 5.6 | 3.2 |
| 2 | 26.74 | 16.9 | 9.3 | 17.9 | 9.7 | 5.5 | 21 | 11.8 | 6.7 | 22.9 | 13.4 | 7.6 |
| 3 | 50.6 | 18.6 | 11.07 | 40.6 | 15.8 | 9.4 | 42.6 | 17 | 9.9 | 42.6 | 17.4 | 10 |
| 4 | 25.2 | 17.8 | 9.4 | 16.1 | 10.6 | 5.8 | 19.6 | 13.3 | 7.2 | 22.3 | 15.5 | 8.3 |
| 5 | 47.3 | 16.8 | 10.3 | 29.2 | 8.3 | 6 | 36.2 | 12 | 7.9 | 40.1 | 13.9 | 8.8 |
| 6 | 41.9 | 16.2 | 8.6 | 27 | 8.5 | 5.4 | 33.9 | 11.9 | 6.8 | 38.1 | 14.2 | 7.7 |
| AVG ± STD | 33.9 ± 15.1 | 15.6 ± 4.2 | 8.7 ± 2.6 | 22.7 ± 12.3 | 9.3 ± 4.3 | 5.6 ± 2.5 | 26.9 ± 12.9 | 11.7 ± 4.1 | 6.9 ± 2.4 | 29.2 ± 13.1 | 13.3 ± 4.1 | 7.6 ± 2.3 |
| 7 | 66.4 | 30.3 | 16.7 | 67.4 | 31.2 | 17.1 | 67.1 | 30 | 16.8 | 67.1 | 30 | 16.7 |
| 8 | 34.4 | 18.3 | 8.7 | 38.3 | 21.8 | 9.9 | 36.7 | 20.4 | 9.3 | 36.4 | 20.2 | 9.3 |
| 9 | 57.7 | 25.7 | 13.2 | 45 | 19.3 | 10.2 | 51.5 | 23 | 11.9 | 55.5 | 25.1 | 12.9 |
| 10 | 62.1 | 27.2 | 14.4 | 64.1 | 26 | 14.1 | 62.3 | 25.3 | 13.7 | 61.1 | 25 | 13.6 |
| 11 | 46.7 | 29.5 | 17.8 | 31.4 | 13.3 | 9.2 | 37.4 | 18.5 | 12.1 | 40.9 | 22.1 | 14 |
| AVG ± STD | 53.5 ± 12.9 | 26.2 ± 4.8 | 14.2 ± 3.6 | 49.2 ± 15.9 | 22.3 ± 6.8 | 12.1 ± 3.4 | 51.0 ± 13.9 | 23.4 ± 4.5 | 12.7 ± 2.7 | 52.2 ± 13.1 | 24.5 ± 3.7 | 13.2 ± 2.5 |
Figure 3(a) Comparison of dosimetric parameters between anatomic and functional plans for small tumor cases and (b) for large tumor cases.
The prescription dose, conformity index (CI), heterogeneity index (HI) and the number of monitor units (MU) in the anatomical and functional IMRT plans for the 11 patients
| | | | | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NSCLC | 6000 | 62.1 | 0.34 | 0.08 | 741 | 102.6 | 0.31 | 0.11 | 999 | 102.6 |
| 2 | NSCLC | 7400 | 119.5 | 0.68 | 0.07 | 387 | 101.9 | 0.62 | 0.10 | 724 | 101.9 |
| 3 | Thymoma | 5400 | 216.7 | 0.56 | 0.10 | 513 | 102.3 | 0.53 | 0.15 | 605 | 102.3 |
| 4 | SCLC | 5400 | 253.5 | 0.56 | 0.14 | 551 | 102.2 | 0.47 | 0.13 | 1182 | 102.2 |
| 5 | Thymoma | 5040 | 260.7 | 0.57 | 0.12 | 517 | 102.4 | 0.52 | 0.15 | 705 | 102.4 |
| 6 | Esophagus | 5040 | 393.2 | 0.64 | 0.11 | 734 | 102.4 | 0.75 | 0.13 | 790 | 102.4 |
| 7 | NSCLC | 5000 | 639.8 | 0.66 | 0.14 | 1060 | 100.9 | 0.64 | 0.11 | 1163 | 100.9 |
| 8 | Esophagus | 5040 | 660.6 | 0.61 | 0.12 | 960 | 102.5 | 0.40 | 0.12 | 973 | 102.5 |
| 9 | NSCLC | 5000 | 716.6 | 0.67 | 0.09 | 867 | 101.9 | 0.60 | 0.13 | 1291 | 101.9 |
| 10 | Esophagus + NSCLC | 5040 | 732.8 | 0.67 | 0.09 | 962 | 102.0 | 0.66 | 0.12 | 1074 | 102.0 |
| 11 | NSCLC | 6000 | 804.9 | 0.61 | 0.10 | 1367 | 101.1 | 0.47 | 0.12 | 1302 | 101.1 |
CI : Conformity index.
PI : prescription isodose line.
PTV : planning target volume within the prescribed isodose volume PI;
V : volume of the prescription isodose line;
PTV : planning targe volume.
HI: Homogenity index.
D2%: represent the doses to 2% of the PTV.
D98%: represent the doses to 98% of the PTV.
DP: Prescription Dose.
Summary of lung dose and critical organs for anatomic and functional treatment plans among 11 thoracic cancer patients
| Total lung | ||
| V5 (%) | 42.77 ± 16.97 | 36.97 ± 17.05 |
| V20(%) | 20.44 ± 6.99 | 18.12 ± 8.11 |
| MLD (Gy) | 11.24 ± 4.03 | 10.19 ± 4.36 |
| 20% Functional lung | ||
| V5 (%) | 34.76 ± 19.21 | 28.61 ± 19.45 |
| V20(%) | 15.22 ± 8.59 | 12.57 ± 8.85 |
| MLD (Gy) | 8.61 ± 4.35 | 7.38 ± 4.59 |
| Heart | ||
| V40 (%) | 16.75 ± 15.05 | 21.87 ± 23.12 |
| Mean dose (Gy) | 16.7 ± 12.78 | 17.31 ± 13.95 |
| Spinal cord | ||
| Maximun (Gy) | 41.58 ± 5.73 | 43.31 ± 4.5 |
| Esophagus | ||
| V35 (%) | 20.36 ± 16.14 | 24.15 ± 17.36 |
| V50 (%) | 11.57 ± 16.95 | 11.57 ± 16.96 |
| Mean dose (Gy) | 15.34 ± 9.23 | 16.22 ± 9.31 |
Abbreviations:
VX(%): volume of an OAR receiving ≧ X Gy; MLD: Mean lung dose; Data presented as mean ± standard deviation.